Get started
Author

Raphael Elie Szalat

Observed names: R Szalat, R. Szalat, Raphael E Szalat, Raphael E. Szalat, Raphael Szalat, Raphaël Szalat, SZALAT, Raphaël, Szalat, R., Szalat, Raphaël
Observed institutions: Boston University, Boston Medical Center, Harvard University, University of Miami, Inserm, VA Boston Healthcare System, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Dana-Farber Cancer Institute, Pitié-Salpêtrière Hospital, Dana-Farber/Harvard Cancer Center, Hôpital Saint-Louis, Hôpital Bichat-Claude-Bernard, Sylvester Comprehensive Cancer Center, Université Paris Diderot, Institut Universitaire d'Hématologie, Différenciation et progression tumorale des lymphocytes, Laboratoire d'hématologie, Université Pierre-et-Marie-Curie
ORCID: 0000-0002-6198-3405
Observed ORCID: 0000-0002-6198-3405
OpenAlex ID: A5055748047
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
2018 · Brian A. Walker, Konstantinos Mavrommatis, et al. · Blood · 471
PDF
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
2018 · Brian A. Walker, Konstantinos Mavrommatis, et al. · Leukemia · 446
PDF
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
2019 · Francesco Maura, Niccoló Bolli, et al. · Nature Communications · 275
PDF
Genomic patterns of progression in smoldering multiple myeloma
2018 · Niccolò Bolli, Francesco Maura, et al. · Nature Communications · 222
PDF
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease
2015 · Camille Cohen, Bruno Royer, et al. · Kidney International · 144
Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases
2014 · Stephanie Harel, Melanie Mohr, et al. · British Journal of Haematology · 130
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines
2017 · F Maura, M Petljak, et al. · Leukemia · 117
PDF
Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy
2011 · Raphael Szalat, Bertrand Arnulf, et al. · Blood · 117
PDF
Good Syndrome: An Adult-Onset Immunodeficiency Remarkable for Its High Incidence of Invasive Infections and Autoimmune Complications
2015 · Marion Malphettes, Laurence Gérard, et al. · Clinical Infectious Diseases · 105
Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study
2020 · Nathanael R Fillmore, Jennifer La, et al. · JNCI Journal of the National Cancer Institute · 102
PDF
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis
2022 · Eli Muchtar, Angela Dispenzieri, et al. · Journal of Clinical Oncology · 93
PDF
A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications
2016 · Jana Jakubikova, Danka Cholujova, et al. · Oncotarget · 71
PDF
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group
2020 · Mehmet Kemal Samur, Anil Aktas Samur, et al. · Journal of Clinical Oncology · 69
Gene Expression Profiles in Myeloma: Ready for the Real World?
2016 · Raphael Szalat, Herve Avet-Loiseau, et al. · Clinical Cancer Research · 62
Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma
2018 · Mehmet Kemal Samur, Stephane Minvielle, et al. · Leukemia · 58
Nucleotide excision repair is a potential therapeutic target in multiple myeloma
2017 · R Szalat, M K Samur, et al. · Leukemia · 58
PDF
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma
2013 · X Leleu, G Fouquet, et al. · Leukemia · 53
Physiopathology of necrobiotic xanthogranuloma with monoclonal gammopathy
2014 · R. Szalat, J. Pirault, et al. · Journal of Internal Medicine · 51
Genomic Instability in Multiple Myeloma
2020 · David A. Alagpulinsa, Raphael E. Szalat, et al. · Trends in cancer · 50
Diagnosis of Castleman Disease
2017 · Raphaël Szalat, Nikhil C. Munshi · Hematology/Oncology Clinics of North America · 49
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma
2023 · Mehmet Kemal Samur, Marco Roncador, et al. · Blood · 48
PDF
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma
2017 · Mariateresa Fulciniti, Joaquin Martinez-Lopez, et al. · Blood · 46
Expressed fusion gene landscape and its impact in multiple myeloma
2017 · A. Cleynen, R. Szalat, et al. · Nature Communications · 45
PDF
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study
2022 · Joshua N. Gustine, Andrew Staron, et al. · American Journal of Hematology · 42
Role of minimal residual disease assessment in multiple myeloma
2024 · Raphael Szalat, Kenneth Anderson, et al. · Haematologica · 38
PDF
Works count: 165
Citation count: 3,551
H-index: 29
I10-index: 49
Year
Topic
Type